Sociedad Americana de Hirudoterapia

Venous Thromboembolism Prophylaxis in Foot and Ankle Surgery: A Worldwide Survey

Research article published in The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons (2024)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosZambelli et al. · The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons, 2024

Abstract

Current recommendations on thromboprophylaxis for foot and ankle (FA) surgery are often inconsistent and generally based on weak evidence. The aim of this survey study was to evaluate the current practice among orthopedic surgeons regarding venous thromboembolism (VTE) prophylaxis following FA surgery. From February 2019 to March 2020, an online questionnaire was sent by e-mail to orthopedic societies across the world. The questionnaire was hosted by the International Society of Thrombosis and Haemostais RedCAP platform. Topics of interest were VTE rates following FA surgery, duration and type of thromboprophylaxis, bleeding complications, VTE risk factors for prophylaxis and use of risk assessment. A total of 693 FA orthopedic surgeons from all continents completed the survey of whom 392 (57%) performed more than 200 FA procedures per year. A total of 669/693 (97%) respondents stated that thromboprophylaxis is necessary in FA surgeries. When thromboprophylaxis was prescribed, half of surgeons prescribed it for the duration of immobilization. Acetylsalicylic acid, low molecular weight heparin and direct-oral anticoagulants were, in this order, the preferred choice. Acetylsalicylic acid and low molecular weight heparin were predominantly prescribed in North America and Europe, respectively. Previous deep vein thrombosis, immobility, obesity and inherited thrombophilia were considered the main risk factors indicative of thromboprophylaxis use. In this survey, most surgeons agree that thromboprophylaxis is indicated for FA surgery, but the prescription, type and duration of prophylaxis differs greatly with a large intercontinental discrepancy. These survey results could be a foundation for developing uniform guidelines to optimize thromboprophylactic strategies in FA procedures around the world.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansAnticoagulantsVenous ThromboembolismAnkleHeparin, Low-Molecular-WeightSurveys and QuestionnairesAspirinPostoperative Complications

Resumen

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Por qué esto importa para la hirudoterapia

Esta encuesta mundial recopiló respuestas de 693 cirujanos ortopédicos de pie y tobillo y encontró que el 97% (669/693) consideró necesaria la tromboprofilaxis después de la cirugía de pie y tobillo; sin embargo, la elección, el tipo y la duración variaron ampliamente, favoreciéndose la aspirina en América del Norte y la heparin de bajo peso molecular en Europa, y los autores señalan que las recomendaciones actuales se basan en evidencia generalmente débil. Su relevancia para la hirudoterapia es periférica, situando el interés en la anticoagulación relacionada con las sanguijuelas dentro del panorama más amplio e incierto de la tromboprofilaxis perioperatoria y la toma de decisiones antitrombóticas. Advertencia honesta: se trata de una encuesta sobre la práctica y opinión declaradas, no de un ensayo de resultados, y no menciona sanguijuelas, hirudin ni ningún agente derivado de sanguijuelas; no debe interpretarse como evidencia sobre la hirudoterapia.

Citación

Venous Thromboembolism Prophylaxis in Foot and Ankle Surgery: A Worldwide Survey.

Zambelli et al. · The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons, 2024

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.